Table 3.

Baseline characteristics and 1-year outcomes of patients with adequate and inadequate dosing of apixaban

	Adequate dosing (n = 1048)	Inadequate dosing (n = 301)	p value
Mean age	72.7 years	77.2 years	< 0.001
Women	46.5%	52.5%	0.06
Mean CHADS-VASc 2 score	3.6	4.1	< 0.001
Mean HAS-BLED score	2.0	2.5	< 0.001
HAS-BLED score  > 3	26.1%	46.8%	< 0.001
History of severe bleeding	1.0%	2.7%	0.06
Severe bleeding under anticoagulation	0.7%	1.7%	0.07
History of moderate bleeding	2.8%	6.0%	< 0.05
GFR 30–59	27.1%	53.8%	< 0.0001
Additional antiplatelet therapy	4.5%	11.0%	< 0.001
1-year outcomes
Stroke	0.6%	0.3%	0.57
Major bleeding	0.9%	1.3%	0.48
Death	4.8%	6.3%	0.31